RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy

In May 2023, the United States Food and Drug Administration approved a Pfizer ⓒ -sponsored (Pfizer, New York, NY, USA) bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) RSV vaccine (Abrysvo TM [Pfizer]) for use during pregnancy to prevent neonatal/infant RSV infection....

Full description

Saved in:
Bibliographic Details
Published in:Obstetrics & gynecology science 2024-11, Vol.67 (6), p.511
Main Authors: Greg J. Marchand, Ahmed Taher Massoud, Ahmed Taha Abdelsattar, Peter A. Mccullough
Format: Article
Language:Korean
Subjects:
Meta-analysis
Neonatology
Respiratory syncytial virus vaccines
Vaccination
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 6
container_start_page 511
container_title Obstetrics & gynecology science
container_volume 67
creator Greg J. Marchand
Ahmed Taher Massoud
Ahmed Taha Abdelsattar
Peter A. Mccullough
description In May 2023, the United States Food and Drug Administration approved a Pfizer ⓒ -sponsored (Pfizer, New York, NY, USA) bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) RSV vaccine (Abrysvo TM [Pfizer]) for use during pregnancy to prevent neonatal/infant RSV infection. In February of 2022, trials sponsored by GSK ⓒ (Brentford, England, UK) on a similar RSVpreF vaccine were halted because of the identification of a safety signal related to preterm births. As these vaccines use identical pre-fusion F-protein technology, we sought to synthesize the existing data on their effectiveness and safety. We identified all randomized controlled trials and used RevMan 5.4.1 (The Cochrane Collaboration, England, UK) to perform the analysis with 95% confidence intervals and risk ratios (RRs). We found many maternal side effects were more prevalent in the RSVpreF group, with more local reactions, blood disorders, fatigue, joint pain, cardiac disorders, headache, fever, gastrointestinal disorders and pregnancy complications. The vaccinated group demonstrated significant reductions in RSV-lower respiratory tract cases (RR, 0.44 [0.33, 0.57]; P
format article
fullrecord <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_4135077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>4135077</kiss_id><sourcerecordid>4135077</sourcerecordid><originalsourceid>FETCH-kiss_primary_41350773</originalsourceid><addsrcrecordid>eNp9i8EKwjAQRHNQsGi_wMv-QKCtLQlexeJZxaNliYlE223JFiF_bw6enctj5jELkVWVVlI3qlqJnPlVpOim1LrOxP18uU3BtvBBYzzh7EcCT5C2JyGZuAeEwc4okbCP7BlGBwPONqQuXTI9MCZGQHqkq0OawTrnDZq4EUuHPdv8x7XYtsfr4STfnrmbgh8wxK4ud02h1O6__QIGkj5c</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy</title><source>Open Access: PubMed Central</source><creator>Greg J. Marchand ; Ahmed Taher Massoud ; Ahmed Taha Abdelsattar ; Peter A. Mccullough</creator><creatorcontrib>Greg J. Marchand ; Ahmed Taher Massoud ; Ahmed Taha Abdelsattar ; Peter A. Mccullough</creatorcontrib><description>In May 2023, the United States Food and Drug Administration approved a Pfizer ⓒ -sponsored (Pfizer, New York, NY, USA) bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) RSV vaccine (Abrysvo TM [Pfizer]) for use during pregnancy to prevent neonatal/infant RSV infection. In February of 2022, trials sponsored by GSK ⓒ (Brentford, England, UK) on a similar RSVpreF vaccine were halted because of the identification of a safety signal related to preterm births. As these vaccines use identical pre-fusion F-protein technology, we sought to synthesize the existing data on their effectiveness and safety. We identified all randomized controlled trials and used RevMan 5.4.1 (The Cochrane Collaboration, England, UK) to perform the analysis with 95% confidence intervals and risk ratios (RRs). We found many maternal side effects were more prevalent in the RSVpreF group, with more local reactions, blood disorders, fatigue, joint pain, cardiac disorders, headache, fever, gastrointestinal disorders and pregnancy complications. The vaccinated group demonstrated significant reductions in RSV-lower respiratory tract cases (RR, 0.44 [0.33, 0.57]; P&lt;0.00001), severe respiratory illness (RR, 0.29 [0.19, 0.44]; P&lt;0.00001), and hospitalizations (RR, 0.40 [0.24, 0.67]; P=0.0005). RSVpreF vaccination was associated with a higher incidence of preterm delivery (RR, 1.24 [1.08, 1.44]; P=0.003). No significant difference in neonatal deaths was observed (RR, 1.42 [0.70, 2.89]; P=0.34). In conclusion, RSVpreF vaccination results in systemic adverse events and an increase in preterm delivery. Vaccination appears to have acceptable short-term newborn safety, but is not related to a significant decrease in neonatal death.</description><identifier>ISSN: 2287-8572</identifier><language>kor</language><publisher>대한산부인과학회</publisher><subject>Meta-analysis ; Neonatology ; Respiratory syncytial virus vaccines ; Vaccination</subject><ispartof>Obstetrics &amp; gynecology science, 2024-11, Vol.67 (6), p.511</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Greg J. Marchand</creatorcontrib><creatorcontrib>Ahmed Taher Massoud</creatorcontrib><creatorcontrib>Ahmed Taha Abdelsattar</creatorcontrib><creatorcontrib>Peter A. Mccullough</creatorcontrib><title>RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy</title><title>Obstetrics &amp; gynecology science</title><addtitle>Obstetrics &amp; Gynecology Science</addtitle><description>In May 2023, the United States Food and Drug Administration approved a Pfizer ⓒ -sponsored (Pfizer, New York, NY, USA) bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) RSV vaccine (Abrysvo TM [Pfizer]) for use during pregnancy to prevent neonatal/infant RSV infection. In February of 2022, trials sponsored by GSK ⓒ (Brentford, England, UK) on a similar RSVpreF vaccine were halted because of the identification of a safety signal related to preterm births. As these vaccines use identical pre-fusion F-protein technology, we sought to synthesize the existing data on their effectiveness and safety. We identified all randomized controlled trials and used RevMan 5.4.1 (The Cochrane Collaboration, England, UK) to perform the analysis with 95% confidence intervals and risk ratios (RRs). We found many maternal side effects were more prevalent in the RSVpreF group, with more local reactions, blood disorders, fatigue, joint pain, cardiac disorders, headache, fever, gastrointestinal disorders and pregnancy complications. The vaccinated group demonstrated significant reductions in RSV-lower respiratory tract cases (RR, 0.44 [0.33, 0.57]; P&lt;0.00001), severe respiratory illness (RR, 0.29 [0.19, 0.44]; P&lt;0.00001), and hospitalizations (RR, 0.40 [0.24, 0.67]; P=0.0005). RSVpreF vaccination was associated with a higher incidence of preterm delivery (RR, 1.24 [1.08, 1.44]; P=0.003). No significant difference in neonatal deaths was observed (RR, 1.42 [0.70, 2.89]; P=0.34). In conclusion, RSVpreF vaccination results in systemic adverse events and an increase in preterm delivery. Vaccination appears to have acceptable short-term newborn safety, but is not related to a significant decrease in neonatal death.</description><subject>Meta-analysis</subject><subject>Neonatology</subject><subject>Respiratory syncytial virus vaccines</subject><subject>Vaccination</subject><issn>2287-8572</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9i8EKwjAQRHNQsGi_wMv-QKCtLQlexeJZxaNliYlE223JFiF_bw6enctj5jELkVWVVlI3qlqJnPlVpOim1LrOxP18uU3BtvBBYzzh7EcCT5C2JyGZuAeEwc4okbCP7BlGBwPONqQuXTI9MCZGQHqkq0OawTrnDZq4EUuHPdv8x7XYtsfr4STfnrmbgh8wxK4ud02h1O6__QIGkj5c</recordid><startdate>20241130</startdate><enddate>20241130</enddate><creator>Greg J. Marchand</creator><creator>Ahmed Taher Massoud</creator><creator>Ahmed Taha Abdelsattar</creator><creator>Peter A. Mccullough</creator><general>대한산부인과학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20241130</creationdate><title>RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy</title><author>Greg J. Marchand ; Ahmed Taher Massoud ; Ahmed Taha Abdelsattar ; Peter A. Mccullough</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_41350773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2024</creationdate><topic>Meta-analysis</topic><topic>Neonatology</topic><topic>Respiratory syncytial virus vaccines</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greg J. Marchand</creatorcontrib><creatorcontrib>Ahmed Taher Massoud</creatorcontrib><creatorcontrib>Ahmed Taha Abdelsattar</creatorcontrib><creatorcontrib>Peter A. Mccullough</creatorcontrib><collection>KISS</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Obstetrics &amp; gynecology science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greg J. Marchand</au><au>Ahmed Taher Massoud</au><au>Ahmed Taha Abdelsattar</au><au>Peter A. Mccullough</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy</atitle><jtitle>Obstetrics &amp; gynecology science</jtitle><addtitle>Obstetrics &amp; Gynecology Science</addtitle><date>2024-11-30</date><risdate>2024</risdate><volume>67</volume><issue>6</issue><spage>511</spage><pages>511-</pages><issn>2287-8572</issn><abstract>In May 2023, the United States Food and Drug Administration approved a Pfizer ⓒ -sponsored (Pfizer, New York, NY, USA) bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) RSV vaccine (Abrysvo TM [Pfizer]) for use during pregnancy to prevent neonatal/infant RSV infection. In February of 2022, trials sponsored by GSK ⓒ (Brentford, England, UK) on a similar RSVpreF vaccine were halted because of the identification of a safety signal related to preterm births. As these vaccines use identical pre-fusion F-protein technology, we sought to synthesize the existing data on their effectiveness and safety. We identified all randomized controlled trials and used RevMan 5.4.1 (The Cochrane Collaboration, England, UK) to perform the analysis with 95% confidence intervals and risk ratios (RRs). We found many maternal side effects were more prevalent in the RSVpreF group, with more local reactions, blood disorders, fatigue, joint pain, cardiac disorders, headache, fever, gastrointestinal disorders and pregnancy complications. The vaccinated group demonstrated significant reductions in RSV-lower respiratory tract cases (RR, 0.44 [0.33, 0.57]; P&lt;0.00001), severe respiratory illness (RR, 0.29 [0.19, 0.44]; P&lt;0.00001), and hospitalizations (RR, 0.40 [0.24, 0.67]; P=0.0005). RSVpreF vaccination was associated with a higher incidence of preterm delivery (RR, 1.24 [1.08, 1.44]; P=0.003). No significant difference in neonatal deaths was observed (RR, 1.42 [0.70, 2.89]; P=0.34). In conclusion, RSVpreF vaccination results in systemic adverse events and an increase in preterm delivery. Vaccination appears to have acceptable short-term newborn safety, but is not related to a significant decrease in neonatal death.</abstract><pub>대한산부인과학회</pub><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2287-8572
ispartof Obstetrics & gynecology science, 2024-11, Vol.67 (6), p.511
issn 2287-8572
language kor
recordid cdi_kiss_primary_4135077
source Open Access: PubMed Central
subjects Meta-analysis
Neonatology
Respiratory syncytial virus vaccines
Vaccination
title RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T13%3A00%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RSVpreF%20vaccination%20in%20pregnancy:%20a%20meta-analysis%20of%20maternal-fetal%20safety%20and%20infant%20efficacy&rft.jtitle=Obstetrics%20&%20gynecology%20science&rft.au=Greg%20J.%20Marchand&rft.date=2024-11-30&rft.volume=67&rft.issue=6&rft.spage=511&rft.pages=511-&rft.issn=2287-8572&rft_id=info:doi/&rft_dat=%3Ckiss%3E4135077%3C/kiss%3E%3Cgrp_id%3Ecdi_FETCH-kiss_primary_41350773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=4135077&rfr_iscdi=true